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Abstract
Background: Interleukin-6 (IL-6) promoter polymorphisms at positions -597(GÆA), -572
(GÆC) and -174(GÆC) were shown to have a clinical impact on different major diseases. At
present PCR-SSP protocols for IL-6
-597/-572/-174haplotyping are elaborate and require large
amounts of genomic DNA.
Findings: We describe an improved typing technique requiring a decreased number of PCR-
reactions and a reduced PCR-runtime due to optimized PCR-conditions.
Conclusion: This enables a fast and efficient determination of IL-6
-597/-572/-174haplotypes in
clinical diagnosis and further evaluation of IL-6 promoter polymorphisms in larger patient cohorts.
Findings
Interleukin-6 (IL-6) is a pleiotropic cytokine with a broad
range of effects that is produced by a variety of different
cells and plays a crucial role at the interface of adoptive and
innate immunity. The increased knowledge about indivi-
dual genetic susceptibility of the immune system led to the
identification of three single biallelic nucleotide poly-
morphisms (SNP) within the promoter region of the IL-6
gene at positions -597(GÆA) (rs1800797), -572(GÆC)
(rs1800796) and -174(GÆC) (rs1800795) [1,2]. The three
SNPs were shown to be in linkage disequilibrium and
naturally occurring IL-6
-597/-572/-174haplotypes have been
characterized [2].
A number of recent studies investigated the clinical impact
of the IL-6 promoter polymorphisms on different major
diseases such as chronic obstructive pulmonary disease
[3,4],viralinfections[5],gout[6],osteoporosis[7],diabetes
[8] or allograft survival [9]. Our own group recently
presented evidence that the IL-6 promoter
-597/-572/-174gen-
otype affects IL-6 secretion [10].
At present, typing of IL-6
-597/-572/-174haplotypes requires
an elaborate and time-consuming protocol [2]. A twelve-
reaction PCR-SSP system with eight different allele-specific
primers (AS1-AS8) is needed in order to identify both
-597/-572/-174haplotypes for the three biallelic sites in each
individual tested. Since PCR-SSP is DNA-consuming, this
procedure requires at least 500 ng genomic DNA; this,
however, may be critical with regard to a retrospective
analysis, or when valuable samples need to be analyzed.
However for subsequent confirmatory investigations of
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technique is needed.
Here we report a modified PCR-SSP protocol which is
suitable for the genotyping of IL-6
-597/-572/-174haplo-
types in the Caucasian population. It is faster, less
labour-intensive and requires less DNA, since only four
instead of twelve PCR reactions are necessary in order to
detect all relevant
-597/-572/-174haplotypes in the Cauca-
sian population (Table 1).
For the isolation of genomic DNA from 200 μLw h o l e
blood, we used the QIAamp® DNA Blood Mini Kit
(Qiagen, Hilden, Germany) according to the manufac-
turer’s standard protocol. The DNA concentration was
estimated from the absorbance at 260 nm using a UV-
spectrophotometer (GeneQuant pro;A m e r s h a mB i o s -
ciences, Freiburg, Germany). For validation, DNA sam-
ples (n = 100) from a previous study [10] genotyped
according to the protocol by Terry et al. [2] were used.
Four forward (AS1-F1g, AS2-F3a, AS3-F3g, AS4-F3c) and
two reverse primers (AS7-R1c, AS8-R1g) specific for the
typing of the AGC (Primermix I), GGC (II), GGG (III)
and GCG (IV) IL-6
-597/-572/-174haplotype respectively
were selected. While primers AS1-F1g, AS7-R1c and AS8-
R1g have been adopted from the original protocol [2],
primers AS2-F3a, AS3-F3g and AS4-F3c have been
optimized for uniform PCR-conditions (Table 2).
According to an optimized protocol for PCR-SSP [11]
reactions were carried out in a total volume of 10 μL,
Table 1: Interleukin-6 Promoter
-597/-572/-174Haplotype Frequencies in different caucasian cohorts
Haplotypes major
(minor)
healthy blood donors (n = 100)
[Müller-Steinhardt et al. 2006]
healthy controls (n = 182)
[Terry et al. 2000]
kidney recipients (n = 158)
[Müller-Steinhardt et al. 2004]
All (n = 440)
number [%] number [%] number [%] number [%]
GGG 113 56.5 195 53.6 165 52.2 473 53.8
AGC 74 37.0 147 40.4 135 42.7 356 40.4
GCG 11 5.5 19 5.2 15 4.7 45 5.1
GGC 2 1 2 0.6 1 0.3 5 0.6
(AGG) 0 0 1 0.3 0 0 1 0.1
( A C G ) 0 00 00 0 0 0
(ACC) 0 0 0 0 0 0 0 0
( G C C ) 0 00 00 0 0 0
total 200 100 364 100 316 100 880 100
Table 2: Primer Sequences and Combinations used in PCR-SSP-typing for Interleukin-6 Promoter
-597/-572/-174Haplotype
Primermix Primer Sequence Product
Size [bp]
- 597
Genotype
- 527
Genotype
- 174
Genotype
Detected
major & (minor) Haplotypes
I AS2-F3a
AS8-R1g
5'-tgaagtaactgcacgaaatttgagga-3'
5'-tgcaatgtgacgtcctttagcatg-3'
473 A - C AGC
(ACC)
II AS1-F1g
AS8-R1g
5'-aagtaactgcacgaaatttgaggg-3'
5'-tgcaatgtgacgtcctttagcatg-3'
471 G - C GGC
(GCC)
III AS3-F3g
AS7-R1c
5'-grtggccaggcagttctacaacagccg-3'
5'-tgcaatgtgacgtcctttagcatc-3'
449 - G G GGG
(AGG)
IV AS4-F3c
AS7-R1c
5'-grtggccaggcagttctacaacagccc-3'
5'-tgcaatgtgacgtcctttagcatc-3'
449 - C G GCG
(ACG)
b-globF4
b-globR5
5'-gcttaccaagctgtgattcc-3'
5'-aaggtgcccttgaggttgtc-3'
731
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specific forward and reverse primers, 0.2 μMe a c ho ft h e
internal control primers, 10 mM Tris-HCl, 50 mM KCl,
1.5 mM MgCl2, 0.01% BSA, 5% glycerol, 0.1 mg/mL
cresol red, and 0.4 U Taq DNA polymerase.
PCR-SSP was performed with the following cycling
program: a 2-min initial denaturation at 95°C, followed
by 10 cycles of 15 s denaturation at 95°C and 1 min
annealing/extension at 65°C, followed by 20 cycles of
15 s denaturation at 95°C, 1 min annealing at 61°C,
and 30 s extension at 72°C. Using a PTC-200 cycler
(BioRad), the total runtime of the PCR-program was
68 min. The amplification products were separated on
2% agarose gels containing 0.5 ng/mL ethidium bromide
in a rapid agarose gel electrophoresis (RAGE®; Cascade
Biologics, Portland, OR, USA) chamber for 5 min at
25 V/cm. The results were obtained by a visual inspec-
tion of the gels and documented using a UV documenta-
tion device with charge-coupled device (CCD) camera
(UVP, Upland, CA, USA).
First-line validation was carried out by genotyping seven
reference samples representing all relevant
-597/-572/-174hap-
lotypes of the Caucasian population (GGG, AGC, GCG,
GGC). The genotypes were as follows: AGC/GGG, GGG/
GGG, AGC/AGC, GGG/GCG, AGC/GCG, AGC/GGC and
GGG/GGC. Our modified PCR-SSP technique confirmed
the typing results of the reference samples in all cases
(Figure 1).
Additional validation of the technique could be achieved
by retyping 100 healthy blood donor samples previously
genotyped according to the protocol by Terry et al. [10].
Our modified technique confirmed all previous typing
results unambiguously (data not shown).
PCR-SSP techniques are widely employed for the
genotyping of SNPs. After PCR and agarose gel electro-
phoresis, the genotyping result is evaluated by the
presence or absence of an allele-specific PCR product.
Moreover, PCR-SSP-typing is suitable for haplotyping of
neighbouring SNPs; furthermore, the presence of two
alleles on one chromosome can be demonstrated when
two appropriate allele-specific primers are combined in a
single PCR-reaction. Consequently, complete typing of
three neighbouring biallelic SNPs requires twelve PCR-
reactions! Since this procedure is very extensive and
time-consuming it is not suitable for the typing of larger
cohorts.
In our study, we describe a modified PCR-SSP protocol
which is suitable for rapid IL-6
-597/-572/-174haplotyping
focusing on the four major
-597/-572/-174haplotypes (AGC,
GGC, GGG, GCG) representing 99.9% of all haplotypes
Figure 1
Validation of the optimized PCR-SSP protocol by
typing of seven reference DNA-samples. Two primers
specific for the typing of the AGC (Primermix I), GGC (II),
GGG (III) and GCG (IV) IL-6
-597/-572/-174haplotype respectively
were used. The amplification product (731 bp) of the internal
control is marked by an arrowhead. Genotyping results were as
expected (AGC/GGG, GGG/GGG, AGC/AGC, GGG/GCG,
AGC/GCG, AGC/GGC, GGG/GGC).
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instead of twelve, PCR-reactions are needed and a
protocol with optimized sensitivity is used [11], the
amount of required genomic DNA could be reduced
from 500 to 100 ng per genotype. This can be extremely
valuable, especially if samples of limited quantity have
to be analyzed.
Notably, our protocol does not distinguish between the
GGG and AGG
-597/-572/-174haplotype, which has only been
detected in one Caucasian individual so far (Table 1).
However, as its frequency is extremely low (0.1%), this
would not affect the overall outcome of association studies.
Furthermore, ACC, ACG and GCC also represent minor
597/-572/-174haplotypes that cannot be distinguished likewise.
Even though they have not been observed among Cauca-
sians and are only of theoretical importance, it cannot be
ruled out that they might occur in other populations as well.
In order to run all four PCR-reactions under identical
conditions, we optimized the selection of the allele-specific
primers. Thereby, the runtime of the PCR-procedure could
be reduced from 110 to 68 min with an overall analysis
time of approximately 2 hours including all pipetting
procedures, DNA-isolation (30 min), electrophoresis
(10 min) and documentation (5 min).
In summary, we optimized a previous PCR-SSP protocol
for IL-6
-597/-572/174haplo-typing of Caucasian indivi-
duals with regard to the number of PCR-reactions, the
amount of genomic DNA required and overall runtime.
This method represents an important prerequisite for
further evaluating the clinical impact of IL-6 promoter
polymorphisms in larger cohorts.
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